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Behaviour of Factors II, VII, IX and X in Bleeding Complications
During Long-Term Treatment with Coumarin
Fronz'the Haernatology Section of the Departrnent of Internal Medicine (Head: Prof. J. Mulder,
M.D.), Unioersity Hospital, and tbe Tbrombosi.s Service (Head: E. A. Loeliger, M.D.), Leyden,
The Netherlands
E .  A .  L o e l i g e r ,  A .  H e n s e n ,  M i e k e  J .  M a t t e r n
a n d H . C . H e m k e r
F .  K .  S C H A T T A U E R - V E R L A G  .  S T U T T G A R T
In a recent publication we reported on rhe behaviour of Factors II, VII, IX,
and X during adequate long-term treatment with various coumarin derivatives
(3). The activity of the four factors appeared to be lowered almost equally, to
a mean activity of about 200/o of normal. Most surprisingly, however, and at
that time inexplicably, the mean thrombotest activity was not lowered accord-
ingly, displaying instead a stronger depression, down to about. l3'0/o of normal,
on the ayerage.
Since then we have collected data concerning the behaviour of Factors II,
VII, IX, and X in 20 cases of bleeding complications during long-term treatment
with the coumarin derivative phenprocoumon (Marcoumar "Roche"). The results
of this study will be given here.
Material and Methods
Glassware, thromboplastin, phospholipid, buffer, samples of normal and patient's plasma,
normal BaSOu-adsorbed plasma, artificially Factor II- and X-deficient as well as congenitally
Factor VII- and IX-deficient substrate plasmas were prepared as previously described (3).
Factors II and X were determined only with the artificially factor-deficient substrate plasma,
Factors VII and IX only with the congenitally factor-deficienr substrate plasma.
The coagulation factor assay system and the calculation of the coagulation factor activity
have also been published earlier (3).
Patients and Normal Controls
During a period of several months, all bleeding complications in our material of about 1300
patients under the care of the thrombosis service were recorded. Those occurring in patients
treated for more than 3 months and displaying no evidence of sudden drange in coagulability
prior to bleeding were chosen for the coagulation factor study. The normal controis were taken
at r4ndpnt fr'om personnel of the University Hospital. Samples from both patients and normals
were not taken after fastine.
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Results
Most of the 20 patients, at the time of bleeding, showed unusually strong
hypocoagulability, as reflected by the mean thrombotest value of about 5olo of
noi*al. The individual as well as the mean values are given in Table 1.
Statistical analysis"' of the figures revealed no statistically significant diffe-
rence between the mean values of the 4 factors (p : O.+). Individually consid-
ered, however, the coefficient of variation of the drance fluctuation appeared to
Table 1r Activity of coagulation factors II, VII, IX, and X in coumarin-treated patients
suffering ftcim-Sleeding complications. Patients nr. l, 3, 4, 6-1L, 73, 15, and 79 displayed
macrohaimaturia, patient w. 2 cerebral haemorrhage, patient nr. 5 a traumatic spleen ruplure,
coagulation factor activity
(per centage)patient nr.
1 .
2.
3.
4
5.
6.
7.
8 .
9.
lu.
1 1 .
72.
13.
74 .
15 .
L6 .
1,7.
18 .
19.
) d
XIXWII I
7.5
18.0
3.5
12.0
79.0
5 .5
10.0
9.5
7.5
8.5
4.0
1 1 . 0
19.0
23.0
5.5
26.0
1 7  A
,,^ ^
18.5
9.0
18.0
8.0
74.0
16.0
6.0
10.0
8.5
r ' .6
6.0
6.5
) 4 6
24.5
79.O
4.5
4.5
16.0
23.0
.,., A
)'7 d
10.0
22.O
14.0
t n n
8.0
10.0
16.0
8.5
4.0
4.0
8.0
24.0
13.0
8.0
4.O
45.O
26.0
18.0
79.0
10.0
17.0
9.0
10.0
9.5
9.0
13.0
9.0
8.0
72.O
18.0
13.5
5.0
4.0
25.0
Ll.5
23.0
13.0
N 2 0 12.45',0/o 73.8olo 14.30/o 12.@lo
+ \fle are indebted to Dr. E. F. Drion, Head of the Statistics Department T. N. O., The
Flague, for his invaluable help with the statistical analysis,
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patient nr. 12 epistaxis, and patients m. !4, 16-18, and.20 melaena
be 35o/o (30.50/o when the
considerably higher than the
treated patients (3).
values of patient nr.
22olo found in normal
Discussion
77 were omitted), which is
individuals or in adequately
It is our experience that in the beginning of coumarin therapy, bleeding
complications occur as the result of a combined Factor VII- and IX-deficiency,
caused by the relatively rapid disappearance of these 2 coagulation factors when
their synthesis is blocked bv the initial loading dose of coumarin. Bleeding
complications during long-term treatment, on the other hand, appear nor ro
be due to a selective coagulation factor deficiency, as can be concluded from
the present study. Factors II, vII, IX, and X behave as under so-called adequate
therapeutic conditions, except that the average intensity of the decrease is
stronger and the coefficient of variation of the drance fluctuation is higher.
Differences'in activity between the 4 factors are not statistically significant; the
higher chance fluctuation, most likely, is due to the fact that bleeding often inter-
rupts the steady state situation.
Interestingly enough, thrombotest again indic ates a significantly lower
activity than that found for the coagulation factors when determined separately,
the average values being 50/o (read from the producer's standard curve) and l3o/0,
respectively. The size of the disparity appears to be higher than in adequately
treated patients (130/o thrombotest as againsr 2o,o/o factor activity), which can
be explained by the inaccuracy of thrombotest readings for values lower than
50/o of normal. The main difference, however, in both instances is due to a
circulating anticoagulant involved in coumarin therapy, as recently demons-
trated in otrr laboratory (7,2).
Summary
rn 20 patients suffering from bleeding complications during long-term
treatment with phenprocoumon, the depression of the activity of Factors II,
vII' IX and X, on the ayerage, was found to be stronger than in so-called
adequately treated patients, whereas no statistically significant differences could
be demonstrated between the average activity of the 4 factors. The individual
variations between the 4 factors were higher than those found in normal
individuals and adequately treated patients.
Thrombotest activity appeared to be considerably lower than the average
factor activity. This discrepancy is mainly caused by the action of the recently
discovered circulating anticoagulant occurring in coumarin-treated or vitamin
K-deficient patients.
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R6sume
Dans 20 cas de complication h6morragique pendant le traitement prolongd
) la phenprocoumon, la ddpression de'l'activit6 des facteurs II, VII, IX et X
6tait plus accentude, en moyenne, que pendant le traitement ad6quat, tandis
qu'entre les moyennes de l'activitd des 4 facteurs il n'y avait pas de diffdrences
statistiquement significatives. Les variations individuelles des 4 facteurs dtaient
un peu plus accentu6es que celles observ6es chez des individus normaux et dlez
des malades trait6s de fagon ad|quate.
L'activit|, "thrombotest" 6tait considdrablement plus basse que I'activitd
moyenne des 4 facteurs. Cette diffdrence est essentiellement due ) un anticoagu-
lant circulant apparaissant pendant le traitement h, la cotrmarine ou en cas
d'avitaminose K.
Zusammenfassung
ln 20 Flllen von Blutungskomplikation wihrend Langzeitbehandlung mit
Phenprocoumon war die durchschnittliche Senkung der Faktor II-, VII-, IX-
und X-Aktivitdt stlrker als bei xdd.quat behandelten Patienten, jedodr ohne
statistisch signifikanten Unterschied zwischen den 4 Faktoren. Die individuellen
Unterschiede zwisdren den 4 Faktoren waren etwas griifler als die bei Normalen
und adiquat Behandelten gefundenen.
Die Thrombotest-Aktivitat war durchsclnittlidr bedeutend niedriger als die
Faktoren-Aktivitdt. Diese Diskrepanz beruht hauptsidrlich auf der \Tirkung
eines vor kurzem entdeckten, wdhrend Coumarinbehandlung und bei Vitamin-K-
Mangel auftretenden zirkulierenden Antikoagulans.
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